(Journal Article): Genetic Susceptibility to Type 1 Diabetes in the Intracellular Pathway of Antigen Processing - A Subject Review and Cross-Study Comparison
 
Sia C, Weinem M (Department of Immunology, United Biomedical Inc., 25 Davids Drive, Hauppage, New York 11788, USA, csia@unitedbiomedical.com )
 
IN: Rev Diabetic Stud 2005; 2(1):40-52
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Ligand binding groves of MHC class I molecules are able to load a panel of endogenous peptides of varying length and sequence derived from self or foreign origin to activate or deactivate cytotoxic CD8+ T cells. Peptides are assembled with class I molecules by pathways that are either dependent or independent of transport by ABC proteins (TAP) and degradation in the immunoproteasome by its subunits LMP2 and LMP7. Those peptides that require TAP and LMP treatment appear to be subject to control and optimization by TAP for proper customizing and efficient presentation. Therefore, allelic variations in the coding sequences of TAP and LMP were suspected for a long time to be responsible for improper antigen processing, interruption of self-peptide presentation and reduced cell surface expression of MHC class I molecules resulting in the activation of autoreactive CD8+ T cells. In this article we reviewed the controversial findings regarding the role of TAP and LMP genes in autoimmune diabetes and reevaluated data of eleven separate studies in a cross-study analysis by genotype and HLA haplotype matching. We could confirm previous results by showing that TAP2*651-A/F and TAP2*687-A/A are significantly associated with disease, independently of linkage disequilibrium (LD). LMP2-R/H surprisingly seems to be primarily disease-conferring although a weak association with DR4 serotypes can be observed. Our analysis also suggests that LMP7-B/B, TAP1-A/A and TAP2*687-A/B are the protective genotypes and that these associations are not secondary to LD with DRB1. Consequently, intracellular antigen processing associated with TAP- and proteasome-dependent pathways seem to be a critical element in T cell selection for the retention of balanced immunity.

TYPE OF PUBLICATION: Original article

REFERENCES:

1. Townsend A, Ohlen C, Bastin J, Ljunggren HG, Foster L, Karre K. Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature 1989. 340(6233):443-448. [DOD]
2. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986. 44(6):959-968.
3. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991. 351(6324):290-296.
4. Kobayashi H, Kimura S, Aoki N, Sato K, Celis E, Katagiri M. Existence of MHC class I-restricted alloreactive CD4+ T cells reacting with peptide transporter-deficient cells. Immunogenetics 2001. 53(8):626-633.
5. Boyle LH, Goodall JC, Gaston JS. Major histocompatibility complex class I-restricted alloreactive CD4+ T cells. Immunology 2004. 112(1):54-63.
6. Tait BD, Colman PG, Morahan G, Marchinovska L, Dore E, Gellert S, Honeyman MC, Stephen K, Loth A. HLA genes associated with autoimmunity and progression to disease in type 1 diabetes. Tissue Antigens 2003. 61(2):146-153.
7. Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991. 65(2):319-331.
8. Kuzushima K, Sun R, van Bleek GM, Vegh Z, Nathenson SG. The role of self peptides in the allogeneic cross-reactivity of CTLs. J Immunol 1995. 155(2):594-601.
9. Hogquist KA, Gavin MA, Bevan MJ. Positive selection of CD8+ T cells induced by major histocompatibility complex binding peptides in fetal thymic organ culture. J Exp Med 1993. 177(5):1469-1473.
10. Imarai M, Goyarts EC, van Bleek GM, Nathenson SG. Diversity of T cell receptors specific for the VSV antigenic peptide (N52-59) bound by the H-2Kb class I molecule. Cell Immunol 1995. 160(1):33-42.
11. Boehm BO, Bluestone JA. Differential roles of costimulatory signaling pathways in type 1 diabetes mellitus. Rev Diabetic Stud 2004. 1(4):156-164. [DOD]
12. Huang FP, MacPherson GG. Continuing education of the immune system - dendritic cells, immune regulation and tolerance. Curr Mol Med 2001. 1(4):457-468.
13. Ashton-Rickardt PG, Van Kaer L, Schumacher TN, Ploegh HL, Tonegawa S. Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell 1993. 73(5):1041-1049.
14. Bell JI, Denney D Jr, Foster L, Belt T, Todd JA, McDevitt HO. Allelic variation in the DR subregion of the human major histocompatibility complex. Proc Natl Acad Sci U S A 1987. 84(17):6234-6238.
15. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987. 329(6140):599-604.
16. Ikegami H, Kawaguchi Y, Yamato E, Kuwata S, Tokunaga K, Noma Y, Shima K, Ogihara T. Analysis by the polymerase chain reaction of histocompatibility leucocyte antigen-DR9-linked susceptibility to insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1992. 75(5):1381-1385.
17. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mule JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991. 147(4):1453-1459.
18. Joyce S, Mathew JM, Flye MW, Mohanakumar T. A polymorphic human kidney-specific non-MHC alloantigen. Its possible role in tissue-specific allograft immunity. Transplantation 1992. 53(5):1119-1127.
19. Fedoseyeva EV, Tam RC, Popov IA, Orr PL, Garovoy MR, Benichou G. Induction of T cell responses to a self-antigen following allotransplantation. Transplantation 1996. 61(5):679-683.
20. Deverson EV, Gow IR, Coadwell WJ, Monaco JJ, Butcher GW, Howard JC. MHC class II region encoding proteins related to the multidrug resistance family of transmembrane transporters. Nature 1990. 348(6303):738-741.
21. van Bleek GM, Nathenson SG. Presentation of antigenic peptides by MHC class I molecules. Trends Cell Biol 1992. 2(7):202-207.
22. Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992. 8:67-113.
23. Schneider E, Hunke S. ATP-binding-cassette (ABC) transport systems: functional and structural aspects of the ATP-hydrolyzing subunits/domains. FEMS Microbiol Rev 1998. 22(1):1-20.
24. Elliott T. Transporter associated with antigen processing. Adv Immunol 1997. 65:47-109.
25. Nijenhuis M, Hammerling GJ. Multiple regions of the transporter associated with antigen processing (TAP) contribute to its peptide binding site. J Immunol 1996. 157(12):5467-5477.
26. Daniel S, Brusic V, Caillat-Zucman S, Petrovsky N, Harrison L, Riganelli D, Sinigaglia F, Gallazzi F, Hammer J, van Endert PM. Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. J Immunol 1998. 161(2):617-624.
27. Androlewicz MJ, Cresswell P. Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity 1994. 1(1):7-14.
28. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med 1991. 174(2):489-492.
29. Bacik I, Cox JH, Anderson R, Yewdell JW, Bennink JR. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol 1994. 152(2):381-387.
30. Lewis JW, Elliott T. Evidence for successive peptide binding and quality control stages during MHC class I assembly. Curr Biol 1998. 8(12):717-720.
31. Lewis JW, Neisig A, Neefjes J, Elliott T. Point mutations in the alpha 2 domain of HLA-A2.1 define a functionally relevant interaction with TAP. Curr Biol 1996. 6(7):873-883.
32. Hearn AR, de Haan L, Pemberton AJ, Hirst TR, Rivett AJ. Trafficking of exogenous peptides into proteasome-dependent major histocompatibility complex class I pathway following enterotoxin B subunit-mediated delivery. J Biol Chem 2004. 279(49):51315-51322.
33. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E, Pious D, DeMars R. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990. 348(6303):744-747.
34. Van Kaer L, Ashton-Rickardt PG, Ploegh HL, Tonegawa S. TAP1 mutant mice are deficient in antigen presentation, surface class I molecules, and CD4-8+ T cells. Cell 1992. 71(7):1205-1214.
35. Aldrich CJ, Ljunggren HG, Van Kaer L, Ashton-Rickardt PG, Tonegawa S, Forman J. Positive selection of self- and alloreactive CD8+ T cells in Tap-1 mutant mice. Proc Natl Acad Sci U S A 1994. 91(14):6525-6528.
36. Faustman D, Li XP, Lin HY, Fu YE, Eisenbarth G, Avruch J, Guo J. Linkage of faulty major histocompatibility complex class I to autoimmune diabetes. Science 1991. 254(5039):1756-1761.
37. Li F, Guo J, Fu Y, Yan G, Faustman D. Abnormal class I assembly and peptide presentation in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 1994. 91(23):11128-1132.
38. Kawaguchi Y, Ikegami H, Fukuda M, Takekawa K, Fujioka Y, Fujisawa T, Ueda H, Ogihara T. Absence of association of TAP and LMP genes with type 1 (insulin-dependent) diabetes mellitus. Life Sci 1994. 54(26):2049-2053.
39. Chauffert M, Cisse A, Chevenne D, You JF, Michel S, Trivin F. Susceptibility to type 1 diabetes in the Senegalese population is linked to HLA-DQ and not TAP and LMP genes. Diabetes Care 1997. 20(8):1299-1303.
40. Jackson DG, Capra JD. TAP2 association with insulin-dependent diabetes mellitus is secondary to HLA-DQB1. Hum Immunol 1995. 43(1):57-65.
41. Penfornis A, Tuomilehto-Wolf E, Faustman DL, Hitman GA, DiMe (Childhood Diabetes in Finland) Study Group. Analysis of TAP2 polymorphisms in Finnish individuals with type I diabetes. Hum Immunol 2002. 63(1):61-70.
42. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 1995. 268(5210):533-539.
43. Groll M, Coux O. Proteasomes in proteinase and peptidase inhibition: recent potential targets for drug development. H.J. Smith and C. Simons eds., Taylor & Francis Publishers, NY, USA., 2002, pp.62-84.
44. Nielsen M, Lundegaard C, Lund O, Kesmir C. The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics 2005. 57(1-2):33-41.
45. Gaczynska M, Rock KL, Goldberg AL. Role of proteasomes in antigen presentation. Enzyme Protein 1993. 47(4-6):354-369.
46. Michalek MT, Grant EP, Gramm C, Goldberg AL, Rock KL. A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation. Nature 1993. 363(6429):552-554.
47. Sibille C, Gould KG, Willard-Gallo K, Thomson S, Rivett AJ, Powis S, Butcher GW, De Baetselier P. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr Biol 1995. 5(8):923-930.
48. Fehling HJ, Swat W, Laplace C, Kuhn R, Rajewsky K, Muller U, von Boehmer H. MHC class I expression in mice lacking the proteasome subunit LMP-7. Science 1994. 265(5176):1234-1237.
49. van Kaer L, Ashton-Rickardt PG, Eichelberger M, Gaczynska M, Nagashima K, Rock KL, Goldberg AL, Doherty PC, Tonegawa S. Altered peptidase and viral-specific T cell response in LMP2 mutant mice. Immunity 1994. 1(7):533-541.
50. Zhou P, Cao H, Smart M, David C. Molecular basis of genetic polymorphism in major histocompatibility complex-linked proteasome gene (Lmp-2). Proc Natl Acad Sci U S A 1993. 90(7):2681-2684.
51. Momburg F, Ortiz-Navarrete V, Neefjes J, Goulmy E, van de Wal Y, Spits H, Powis SJ, Butcher GW, Howard JC, Walden P, et al. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation. Nature 1992. 360(6400):174-177.
52. Yewdell J, Lapham C, Bacik I, Spies T, Bennink J. MHC-encoded proteasome subunits LMP2 and LMP7 are not required for efficient antigen presentation. J Immunol 1994. 152(3):1163-1170.
53. Deng GY, Muir A, Maclaren NK, She JX. Association of LMP2 and LMP7 genes within the major histocompatibility complex with insulin-dependent diabetes mellitus: population and family studies. Am J Hum Genet 1995. 56(2):528-534.
54. van Endert PM, Liblau RS, Patel SD, Fugger L, Lopez T, Pociot F, Nerup J, McDevitt HO. Major histocompatibility complex-encoded antigen processing gene polymorphism in IDDM. Diabetes 1994. 43(1):110-117.
55. Dyall R, Messaoudi I, Janetzki S, Nikolic-Zugic J. MHC polymorphism can enrich the T cell repertoire of the species by shifts in intrathymic selection. J Immunol 2000. 164(4):1695-1698.
56. Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher HP, Zinkernagel RM, Tonegawa S. Evidence for a differential avidity model of T cell selection in the thymus. Cell 1994. 76(4):651-663.
57. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994. 76(1):17-27.
58. Mathews CE, Pietropaolo SL, Pietropaolo M. Reduced thymic expression of islet antigen contributes to loss of self-tolerance. Ann N Y Acad Sci 2003. 1005:412-417.
59. Nikolich-Zugich J, Fremont DH, Miley MJ, Messaoudi I. The role of mhc polymorphism in anti-microbial resistance. Microbes Infect 2004. 6(5):501-512.
60. Chen M, Abele R, Tampe R. Peptides induce ATP hydrolysis at both subunits of the transporter associated with antigen processing. J Biol Chem 2003. 278(32):29686-29692.
61. van Bleek GM, Nathenson SG. Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 1990. 348(6298):213-216.
62. van Bleek GM, Nathenson SG. The structure of the antigen-binding groove of major histocompatibility complex class I molecules determines specific selection of self-peptides. Proc Natl Acad Sci U S A 1991. 88(24):11032-11036.
63. Grossman Z, Min B, Meier-Schellersheim M, Paul WE. Concomitant regulation of T-cell activation and homeostasis. Nat Rev Immunol 2004. 4(5):387-395.
64. Marsh SG, Bodmer JG, Albert ED, Bodmer WF, Bontrop RE, Dupont B, Erlich HA, Hansen JA, Mach B, Mayr WR, Parham P, Petersdorf EW, Sasazuki T, Schreuder GM, Strominger JL, Svejgaard A, Terasaki PI. Nomenclature for factors of the HLA system, 2000. Tissue Antigens 2001. 57(3):236-283.
65. Colonna M, Bresnahan M, Bahram S, Strominger JL, Spies T. Allelic variants of the human putative peptide transporter involved in antigen processing. Proc Natl Acad Sci U S A 1992. 89(9):3932-3936.
66. Caillat-Zucman S, Bertin E, Timsit J, Boitard C, Assan R, Bach JF. Protection from insulin-dependent diabetes mellitus is linked to a peptide transporter gene. Eur J Immunol 1993. 23(8):1784-1788.
67. Jackson DG, Capra JD. TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility. Proc Natl Acad Sci U S A 1993. 90(23):11079-11083.
68. Ronningen KS, Undlien DE, Ploski R, Maouni N, Konrad RJ, Jensen E, Hornes E, Reijonen H, Colonna M, Monos DS, et al. Linkage disequilibrium between TAP2 variants and HLA class II alleles; no primary association between TAP2 variants and insulin-dependent diabetes mellitus. Eur J Immunol 1993. 23(5):1050-1056.
69. Undlien DE, Akselsen HE, Joner G, Dahl-Jorgensen K, Sovik O, Ronningen KS, Thorsby E. No independent associations of LMP2 and LMP7 polymorphisms with susceptibility to develop IDDM. Diabetes 1997. 46(2):307-312.
70. Ding H, Cheng H, Fu Z, Yan L, Yang G. Relationship of large multifunctional proteasome 7 gene polymorphism with susceptibility to type 1 diabetes mellitus and DR3 gene. Chin Med J (Engl) 2001. 114(12):1263-1266.
71. Ding HL, Cheng H, Fu ZZ, Deng QL, Tang Yan L, Yan T. The relationship of lmp2 and DR3 genes with susceptibility to type I diabetes mellitus in south China Han population. World J Gastroenterol 2000. 6(1):111-114.
72. Ma L, Penfornis A, Wang X, Schoenfeld D, Tuomilehto-Wolf E, Metcalfe K, Hitman G, Faustman D. Evaluation of TAP1 polymorphisms with insulin dependent diabetes mellitus in Finnish diabetic patients. The Childhood Diabetes in Finland (DiMe) Study Group. Hum Immunol 1997. 53(2):159-166.
73. Daniel S, Caillat-Zucman S, Hammer J, Bach JF, van Endert PM. Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J Immunol 1997. 159(5):2350-2357.